ArticleClinical epigenetics2025
Trace element-linked DNA methylation sites and their association with type 2 diabetes and cardiovascular diseases: EPIC-Potsdam cohort study.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epigenetic and genetic factors modifying the association between diet quality and incident type 2 diabetes: the EPIC-Potsdam cohort.Cardiovascular diabetology · 2026Article
- Associations between diet quality, epigenetic aging and epigenome in two population-based cohorts.Nature communications · 2026Article
- Precision Nutrition in Type 2 Diabetes Prevention Through Molecular Nutrigenomic and Epigenetic Modulation of Insulin Signaling and Glucose Metabolism.International journal of molecular sciences · 2026Review
- Dietary bioactive compounds targeting insulin resistance: mechanisms and preventive potential.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe trace elements (TEs) selenium, zinc, copper, manganese, iodine and iron are essential micronutrients that support essential metabolic functions. Imbalance in their homeostasis might contribute to the pathogenesis of major age-related chronic diseases including type 2 diabetes (T2D) and cardiovascular diseases (CVD). Emerging evidence suggests that TEs may affect health outcomes via epigenetic changes. However, few epigenome-wide association studies (EWAS) have explored TE-associated DNA methylation markers and their links to chronic disease outcomes.
methodsWe conducted TE-specific exploratory EWAS using a random subcohort (n = 1030) from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. The association between identified CpG sites and incident chronic diseases was evaluated using a case-cohort design comprising random subcohort participants and incident cases of T2D (n = 654) and CVD (n = 334). DNA methylation was measured with the MethylationEPIC BeadChip array. We used Prentice-weighted Cox proportional hazards regression models to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of TE-associated CpG sites with each incident chronic disease.
resultsIn the copper EWAS, we identified six CpG sites (cg00398673, cg03957124, cg05736499, cg07573872, cg11503550, and cg18513344) that were significantly associated with serum copper concentrations with a False Discovery Rate < 0.05. All associated CpG sites showed lower methylation levels in association with higher serum copper levels. Higher methylation levels of cg00398673 (HR per SD: 0.74, 95% CI 0.63-0.88), cg03957124 (HR per SD: 0.52, 95% CI 0.41-0.66), cg05736499 (HR Q5 vs Q1: 0.25, 95% CI 0.14-0.47), and cg18513344 (HR Q5 vs Q1: 0.37, 95% CI 0.24-0.57) were associated with decreased risk of developing T2D, and higher methylation levels of cg07573872 were associated with decreased risk of developing CVD (HR per SD: 0.85, 95% CI 0.72-0.99). We did not observe any CpG sites that were significantly associated with other TEs.
conclusionsSerum copper levels are inversely associated with a number of CpG sites. Methylation levels at these CpG sites were inversely associated with developing T2D and CVD. These findings may provide new insights on understanding the increased risk of T2D and CVD with elevated blood copper levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.